Unknown

Dataset Information

0

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.


ABSTRACT: The combination of CTLA-4 blockade ipilimumab (Ipi) with VEGF-A blocking antibody bevacizumab (Bev) has demonstrated favorable clinical outcomes in patients with advanced melanoma. Galectin-3 (Gal-3) plays a prominent role in tumor growth, metastasis, angiogenesis, and immune evasion. Here we report that Ipi plus Bev (Ipi-Bev) therapy increased Gal-3 antibody titers by 50% or more in approximately one third of treated patients. Antibody responses to Gal-3 were associated with higher complete and partial responses and better overall survival. Ipi alone also elicited antibody responses to Gal-3 at a frequency comparable to the Ipi-Bev combination. However, an association of elicited antibody responses to Gal-3 with clinical outcomes was not observed in Ipi alone treated patients. In contrast to being neutralized in Ipi-Bev treated patients, circulating VEGF-A increased by 100% or more in a subset of patients after Ipi treatment, with most having progressive disease. Among the Ipi treated patients with therapy-induced Gal-3 antibody increases, circulating VEGF-A was increased in 3 of 6 nonresponders but in none of 4 responders as a result of treatment. Gal-3 antibody responses occurred significantly less frequently (3.2%) in a cohort of patients receiving PD-1 blockade where high pre-treatment serum Gal-3 was associated with reduced OS and response rates. Our findings suggest that anti-CTLA-4 elicited humoral immune responses to Gal-3 in melanoma patients which may contribute to the antitumor effect in the presence of an anti-VEGF-A combination. Furthermore, pre-treatment circulating Gal-3 may potentially have prognostic and predictive value for immune checkpoint therapy.

SUBMITTER: Wu X 

PROVIDER: S-EPMC5993498 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.

Wu Xinqi X   Giobbie-Hurder Anita A   Connolly Erin M EM   Li Jingjing J   Liao Xiaoyun X   Severgnini Mariano M   Zhou Jun J   Rodig Scott S   Hodi F Stephen FS  

Oncoimmunology 20180313 7


The combination of CTLA-4 blockade ipilimumab (Ipi) with VEGF-A blocking antibody bevacizumab (Bev) has demonstrated favorable clinical outcomes in patients with advanced melanoma. Galectin-3 (Gal-3) plays a prominent role in tumor growth, metastasis, angiogenesis, and immune evasion. Here we report that Ipi plus Bev (Ipi-Bev) therapy increased Gal-3 antibody titers by 50% or more in approximately one third of treated patients. Antibody responses to Gal-3 were associated with higher complete and  ...[more]

Similar Datasets

| S-EPMC5509159 | biostudies-literature
| S-EPMC5852008 | biostudies-other
| S-EPMC3575079 | biostudies-literature
| S-EPMC4910727 | biostudies-literature
| S-EPMC6020711 | biostudies-literature
| S-EPMC5809910 | biostudies-literature
| S-EPMC7463444 | biostudies-literature
| S-EPMC6838990 | biostudies-literature
| S-EPMC4963052 | biostudies-literature
| S-EPMC10168111 | biostudies-literature